29 completed, 8 terminated, 5 recruiting, 4 active not recruiting. 30 Phase 1, 14 Phase 2, 2 Not applicable, 1 Early Phase 1, 1 Phase 3.
Follow Anaplastic Oligodendroglioma: new trials by email Literature Review of Anaplastic Oligodendroglioma trials Research Report on Anaplastic Oligodendroglioma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Retifanlimab With or Without Difluoromethylornithine for the Treatment of Progressive High Grade Gliomas Biospecimen Collection, Eflornithine, Lumbar Puncture - Anaplastic Oligodendroglioma, Astrocytoma, IDH-Mutant, Grade 3 | Phase 1 / Phase 2 | Recruiting | Mayo Clinic | 33 | 2026-06-23 | 2026-06-24 |
| Adaptive Radiotherapy and MRIs Based on Patients With Newly Diagnosed High-Grade Glioma Glioblastoma, Anaplastic Astrocytoma | Active not recruiting | Columbia University | 20 | 2024-01-30 | 2026-08-19 | |
| Testing Cerebrospinal Fluid for Cell-free Tumor DNA in Children, Adolescents, and Young Adults With Brain Tumors Anaplastic Astrocytoma, Diffuse Brainstem Glioma | Terminated | Pediatric Brain Tumor Consortium | 57 | 2023-07-12 | 2026-04-23 | |
| A Study of Temodar With Abexinostat (PCI-24781) for Patients With Recurrent Glioma PCI 24781, Temozolomide - Recurrent High Grade Glioma, Anaplastic Astrocytoma | Phase 1 | Recruiting | University of Nebraska | 24 | 2023-06-26 | 2026-09-14 |
| A Pilot Study of SurVaxM in Children Progressive or Relapsed Medulloblastoma, High Grade Glioma, Ependymoma and Newly Diagnosed Diffuse Intrinsic Pontine Glioma SurVaxM for patients with relapsed or progressive MB, HGG or ependymoma ages ≥10 and ≤21 years, SurVaxM for patients with relapsed or progressive MB, HGG or ependymoma ages ≥1 and <10 years, SurVaxM for patients with non-relapsed DIPG post radiation-therapy ages ≥1 and ≤21 years - Medulloblastoma, Glioblastoma Multiforme | Phase 1 | Active not recruiting | Children's Oncology Group | 35 | 2022-07-01 | 2026-06-02 |
| Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms ONC206 - Central Nervous System Neoplasms, Glioblastoma | Phase 1 | Recruiting | Jazz Pharmaceuticals | 102 | 2020-10-26 | 2026-10-23 |
| INCB7839 in Treating Children With Recurrent/Progressive High-Grade Gliomas INCB7839 - Glioblastoma Multiforme, Anaplastic Astrocytoma | Phase 1 | Completed | Pediatric Brain Tumor Consortium | 13 | 2020-07-27 | 2026-10-01 |
| Implantable Microdevice In Primary Brain Tumors Microdevice - Grade II Glioma, Grade III Glioma | Early Phase 1 | Recruiting | Oliver Jonas | 30 | 2020-03-03 | 2026-10-21 |
| Chemotherapy and Radiation Therapy for the Treatment of IDH Wildtype Gliomas or Non-histological (Molecular) Glioblastomas Quality-of-Life Assessment, Questionnaire Administration, Radiation Therapy - Anaplastic Astrocytoma, IDH-Wildtype, Anaplastic Oligoastrocytoma | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 40 | 2020-01-30 | 2026-07-16 |
| Determining Dose of Regadenoson Most Likely to Transiently Alter the Integrity of the Blood-Brain Barrier in Patients With High Grade Gliomas Regadenoson 0.05mg, Regadensoson 0.1mg, Regadensoson 0.2mg - High Grade Glioma, Anaplastic Astrocytoma | Phase 1 | Terminated | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 7 | 2019-12-06 | 2023-10-06 |
| Pediatric Long-Term Follow-up and Rollover Study dabrafenib, trametinib - Diffuse Astrocytoma, Anaplastic Astrocytoma | Phase 4 | Active not recruiting | Novartis Pharmaceuticals | 163 | 2019-11-04 | 2026-08-27 |
| SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors Gemcitabine, ribociclib, sonidegib - Anaplastic Astrocytoma, Anaplastic Ependymoma | Phase 1 | Completed | St. Jude Children's Research Hospital | 68 | 2018-03-05 | 2024-05-31 |
| Proton Beam or Intensity-Modulated Radiation Therapy in Preserving Brain Function in Patients With IDH Mutant Grade II or III Glioma Biospecimen Collection, Intensity-Modulated Radiation Therapy, Laboratory Biomarker Analysis - Anaplastic Astrocytoma, Anaplastic Oligoastrocytoma | Phase 2 | Active not recruiting | NRG Oncology | 120 | 2018-01-23 | 2026-07-28 |
| Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Pediatric Patients With BRAF V600 Mutation Positive LGG or Relapsed or Refractory HGG Tumors Dabrafenib, trametinib, Carboplatin - Diffuse Astrocytoma, Anaplastic Astrocytoma | Phase 2 | Completed | Novartis Pharmaceuticals | 151 | 2017-12-28 | 2023-12-13 |
| NovoTTF-200A Device in Treating Patients With Newly Diagnosed High Risk Oligodendroglioma Wear novoTTF-200A, Quality-of-Life Assessment - Anaplastic Oligodendroglioma, Oligoastrocytoma | Not applicable | Withdrawn | University of Southern California | 2017-12-15 | 2020-12-10 | |
| Phase 1b Study PVSRIPO for Recurrent Malignant Glioma in Children Polio/Rhinovirus Recombinant (PVSRIPO) - Malignant Glioma, Anaplastic Astrocytoma | Phase 1 | Completed | Istari Oncology, Inc. | 8 | 2017-11-07 | 2024-04-08 |
| Neural Stem Cell Based Virotherapy of Newly Diagnosed Malignant Glioma Neural stem cells loaded with an oncolytic adenovirus - Glioma, Anaplastic Astrocytoma | Phase 1 | Completed | Northwestern University | 12 | 2017-04-24 | 2023-01-20 |
| RRx-001 + Radiation + Temozolomide In Newly Diagnosed Glioblastoma and Anaplastic Gliomas RRx-001 dose escalation with TMZ + RT, Radiation, Fixed dose Temozolomide (75 mg/m2) - Glioblastoma, Oligodendroglioma | Phase 1 | Completed | EpicentRx, Inc. | 19 | 2017-02-14 | 2022-05-16 |
| Lapatinib Ditosylate Before Surgery in Treating Patients With Recurrent High-Grade Glioma Laboratory Biomarker Analysis, Lapatinib, Lapatinib Ditosylate - Anaplastic Astrocytoma, Anaplastic Ependymoma | Phase 1 | Completed | National Cancer Institute (NCI) | 29 | 2016-11-07 | 2024-11-06 |
| Phase I Study of Mebendazole Therapy for Recurrent/Progressive Pediatric Brain Tumors Mebendazole - Medulloblastoma, Astrocytoma, Grade III | Phase 1 | Completed | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 16 | 2016-05-01 | 2022-06-23 |
Showing 20 of 52. Sign in to see all of them.
Oligodendroglioma (52) · Astrocytoma (50) · Glioblastoma (46) · Glioma (32) · Brain Neoplasms (20) · Gliosarcoma (16) · Ependymoma (9) · Medulloblastoma (7) · Central Nervous System Neoplasms (4) · Meningioma (4) · Neuroectodermal Tumors, Primitive (4) · Lymphoma, Follicular (3) · Neoplasms (3) · Pinealoma (3) · Recurrence (3)
Neoplasms by Histologic Type (52) · Neoplasms, Glandular and Epithelial (52) · Neoplasms, Nerve Tissue (52) · Neoplasms, Germ Cell and Embryonal (51) · Neuroectodermal Tumors (51) · Neoplasms, Neuroepithelial (50) · Neoplasms (49) · Neoplasms by Site (28) · Nervous System Diseases (28) · Nervous System Neoplasms (28) · Brain Diseases (26) · Central Nervous System Diseases (26) · Central Nervous System Neoplasms (24) · Glioma (20) · Brain Neoplasms (6)
Temozolomide (7) · Magnetic Resonance Spectroscopy (4) · Carboplatin (3) · Carmustine (3) · Flucytosine (3) · trametinib (3) · Radiation (2) · Specimen Handling (2) · Surgical Procedures, Operative (2) · dabrafenib (2) · vocimagene amiretrorepvec (2) · (5-(2,4-bis((3S)-3-methylmorpholin-4-yl)pyrido(2,3-d)pyrimidin-7-yl)-2-methoxyphenyl)methanol (1) · 2-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole (1) · Ascorbic Acid (1) · Bevacizumab (1)
National Cancer Institute (NCI) (5) · Pediatric Brain Tumor Consortium (3) · Tocagen Inc. (3) · Mayo Clinic (2) · Novartis Pharmaceuticals (2) · Roswell Park Cancer Institute (2) · Shandong Lanjin Pharmaceuticals Co.,Ltd (2) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (2) · University of Nebraska (2) · Andrew B Lassman, MD (1) · Angiochem Inc (1) · Annick Desjardins (1) · Case Comprehensive Cancer Center (1) · Children's Oncology Group (1) · City of Hope Medical Center (1)
United States (46) · Canada (4) · Argentina (2) · Australia (2) · Belgium (2) · Brazil (2) · China (2) · Czechia (2) · Denmark (2) · Finland (2) · France (2) · Germany (2) · Israel (2) · Italy (2) · Japan (2)
Asha Das, MD (3) · Katherine E Warren, M.D. (2) · Alexandra Miller, MD, PhD (1) · Andrew B. Lassman, MD (1) · Annick Desjardins, MD (1) · Arti B Gaur, PhD (1) · Behnam Badie (1) · Bryan Oronsky (1) · Clare Twist, MD (1) · Daniel Landi, MD (1) · Darell Bigner, MD, PhD (1) · David Peereboom, MD (1) · David R Grosshans (1) · Debra N Yeboa (1)
PMID 21242491, PMID 24786603, PMID 25098701, PMID 25338318, PMID 26860632, PMID 29762717, PMID 34214495, PMID 34331515, PMID 35417530, PMID 37004712, PMID 37610803, PMID 37643378, PMID 37733309, PMID 38182653, PMID 38215438, PMID 38216554, PMID 40132910, PMID 40225909, PMID 41740060, PMID 9390198
UM1CA081457 (3), P30CA016056 (2), UM1CA137443 (2), 2015 (1), 2023 (1), P30CA014089 (1), P30CA015083 (1), P30CA036727 (1), P50CA108961 (1), P50CA221747 (1), R01CA125244 (1), R01CA158318 (1), U01CA081457 (1), U01CA137443 (1), U10CA180868 (1)